Appendix 1

- Clinical and Laboratory Standards Institute M27.

Antifungal agents	Susceptible	Susceptible dose dependent	Intermediate	Resistant
Fluconazole^*	≤8	16-32		≥64
Itraconzole	≤0.125	0.25-0.5		≥1
Flucytosine	≤4		8-16	≥32
Caspofungin	≤2^*^†
Voriconazole	<1			>4

↵* Candida krusei recovered from super infections have not been found to be susceptible to fluconazole and may require alternative antifungal therapy.
^† In clinical studies, voriconazole MIC₉₀ for C. glabrata baseline was 4 ug/ml; 13/50 (26%). C. glabrata baseline isolates were resistant (MIC ≥4ug/ml) to voriconazole. However, based on 1054 isolates tested in surveillance studies the MIC₉₀ was 1 ug/ml.